The other Genelabs story

With the future of its Prestara prasterone hormone for systemic lupus erythematosus again clouded by disappointing data, Genelabs Technologies Inc. has particular reason to be glad it can point to progress in another long-time area of focus for the company: HCV drug discovery.

A recent deal with Gilead Sciences Inc. covering GNLB's nucleoside compounds against the RNA-dependent RNA polymerase

Read the full 581 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE